Literature DB >> 1851703

Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle.

D H Maurice1, D Crankshaw, R J Haslam.   

Abstract

Previous studies have established that nitrovasodilators potentiate the inhibition of platelet function by activators of adenylyl cyclase, but uncertainty exists as to whether a comparable effect is seen in vascular smooth muscle. We initially studied the effects of the nitrovasodilators, sodium nitroprusside (SNP) and 3-morpholinosydnonimine (SIN-1), on the relaxation by isoprenaline of rat aortic smooth muscle that had been precontracted by phenylephrine. Concentrations of SNP (0.25 nM) and SIN-1 (30 nM) that relaxed aortic smooth muscle less than 30% alone, caused significant (3-fold) decreases in the IC50 values for isoprenaline. The cAMP phosphodiesterase inhibitors, cilostamide (20 nM) and Ro 20-1724 (10 microM), caused comparable reductions in the IC50 values for isoprenaline. At these concentrations, each of the four compounds also increased the maximum relaxation achieved with isoprenaline. Even more marked synergistic interactions were observed between isoprenaline and either the nitrovasodilators or the cAMP phosphodiesterase inhibitors when these compounds were added simultaneously before contraction of aortic smooth muscle by phenylephrine. Thus, concentrations of SNP (5 nM), SIN-1 (1 microM), cilostamide (1 microM) and Ro 20-1724 (100 microM) that inhibited contraction by less than 30% decreased the IC50 values for isoprenaline by 8- to 10-fold. At the above concentrations, these compounds each caused a supra-additive inhibition of contraction when added with 100 nM isoprenaline. Thus, synergism between nitrovasodilators and isoprenaline, an activator of adenylyl cyclase, could be detected in vascular smooth muscle and was particularly marked when inhibition of contraction was studied. This action of nitrovasodilators resembled that of inhibitors of cAMP phosphodiesterase.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1851703     DOI: 10.1016/0014-2999(91)90048-u

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  9 in total

1.  Effect of cyclic GMP-dependent vasodilators on the expression of inducible nitric oxide synthase in vascular smooth muscle cells: role of cyclic AMP.

Authors:  M Boese; R Busse; A Mülsch; V Schini-Kerth
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

2.  Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.

Authors:  N Komas; C Lugnier; J C Stoclet
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

3.  Intimal hyperplasia in human uterine arteries accompanied by impaired synergism between prostaglandin I2 and nitric oxide.

Authors:  S Obayashi; T Aso; J Sato; H Hamasaki; H Azuma
Journal:  Br J Pharmacol       Date:  1996-11       Impact factor: 8.739

4.  Effects of cyclic GMP elevation on isoprenaline-induced increase in cyclic AMP and relaxation in rat aortic smooth muscle: role of phosphodiesterase 3.

Authors:  E Delpy; H Coste; A C Gouville
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

5.  Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta.

Authors:  S M Yu; S C Kuo
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

6.  Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.

Authors:  A E Eckly; C Lugnier
Journal:  Br J Pharmacol       Date:  1994-10       Impact factor: 8.739

7.  Functional and molecular characterization of endothelium-dependent and endothelium-independent relaxant pathways in uterine artery of non-pregnant buffaloes.

Authors:  Udayraj P Nakade; Abhishek Sharma; Priyambada Kumari; Shirish Bhatiya; Sooraj V Nair; K N Karikaran; Vipin Sharma; Soumen Choudhury; Satish Kumar Garg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-09-07       Impact factor: 3.000

8.  The interaction of alpha-human atrial natriuretic peptide (ANP) with salbutamol, sodium nitroprusside and isosorbide dinitrate in human bronchial smooth muscle.

Authors:  J E Nally; R A Clayton; N C Thomson; J C McGrath
Journal:  Br J Pharmacol       Date:  1994-12       Impact factor: 8.739

9.  Col4a1 mutation in mice causes defects in vascular function and low blood pressure associated with reduced red blood cell volume.

Authors:  Tom Van Agtmael; Matthew A Bailey; Ursula Schlötzer-Schrehardt; Eilidh Craigie; Ian J Jackson; David G Brownstein; Ian L Megson; John J Mullins
Journal:  Hum Mol Genet       Date:  2010-01-07       Impact factor: 6.150

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.